<DOC>
	<DOCNO>NCT01012492</DOCNO>
	<brief_summary>The primary objective study determine safety tolerability add abatacept acute Graft versus Host Disease transplant malignant disease use unrelated donor bone marrow peripheral blood stem cell graft .</brief_summary>
	<brief_title>Safety Tolerability Trial Abatacept-based Immunosuppression Prevention Acute Graft Versus Host Disease ( aGVHD ) During Transplant</brief_title>
	<detailed_description>Acute Graft versus Host Disease ( aGvHD ) deadly complication face child allogeneic hematopoietic stem cell transplant ( HSCT ) . aGvHD occur , large part , T cell bone marrow graft `` accept '' presence transplant recipient 's cell , mount severe , debilitating , often deadly attack recipient , strike skin , liver , gastrointestinal track , prominently . For patient receive bone marrow unrelated donor , rate aGvHD reach high 80 % , half patient die complication . These serious outcome occur despite best effort aGvHD prevention . Given lack success prevent aGvHD current therapy , novel therapy prevent disease desperately need . In study , plan test novel drug prevent aGvHD . This drug , know abatacept , specifically block activation pathway critical T cell function know `` T cell costimulation . '' In particular , block CD28-mediated costimulation pathway critical optimal T cell activation proliferation . My research group do extensive pre-clinical work compound . Our work demonstrate efficacy induce immune tolerance transplantation mouse model primate model . In addition , patient trial demonstrate block CD28-directed T cell costimulation prevent T cell-mediated disease , include rheumatoid arthritis psoriasis , improve solid organ transplant acceptance . Abatacept currently FDA approve use rheumatoid arthritis . Given drug 's safety efficacy profile , grant IND-exemption FDA inclusion abatacept GvHD-prevention strategy . This safety tolerability study addition abatacept GvHD-prophylaxis regimen . Thus , primary objective study determine safety tolerability addition abatacept aGvHD prophylaxis transplant malignant hematologic disease use unrelated donor bone marrow peripheral blood stem cell graft . Three secondary objective also address : 1 . We estimate incidence severity aGvHD patient receive abatacept-based protocol . 2 . We determine immune phenotype donor cell patient receive abatacept . 3 . We determine ability donor T-cells patient receive abatacept respond polyclonal recipient-specific immune stimulation . These secondary objective allow u determine impact abatacept-containing GvHD prevention T cell alloreactivity T cell-mediated protective immunity . This study patient older 12 diagnosed high-risk leukemia unrelated bone marrow transplant plan . We plan enroll 10 patient study , 1-year period open trial . Of ten patient , least five pediatric patient ; five may adult patient take care Winship Cancer Center physician . All clinical study coordination biologic study perform CHOA personnel . Participants receive one two standard myeloablative conditioning regimen stem cell transplant , receive aGvHD prophylaxis regimen include cyclosporine , methotrexate , abatacept . They immunologic analysis 1 year transplant clinical analysis 3 year transplant .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Patients AML , without history myelodysplastic syndrome one follow category . ( ) Patients first complete remission highrisk feature 2 . Patients ALL , either follow category : 1 . In 2nd great complete remission ( complete remission define &gt; 5 % blast marrow ) 2 . Delayed 1st CRFailure achieve complete remission single round induction therapy 3 . Patients undifferentiated biphenotypic leukemia 1st great complete remission . 4 . Patients Myelodysplastic Syndrome ( ) IPSS score &gt; 1.5 &lt; 10 % blast bone marrow time transplant . These condition include : 1 . Refractory anemia 2 . Refractory anemia ring sideroblast 3 . Refractory cytopenia multilineage dysplasia 4 . Refractory cytopenia multilineage dysplasia ring sideroblast 5 . Refractory anemia excess blasts1 ( 510 % blast ) 6 . Refractory anemia excess blasts2 ( 1020 % blast ) 7 . Myelodysplastic syndrome , unclassified 8 . MDS associate isolated del ( 5q ) 9 . Patients diagnose AML CR1 initial diagnosis MDS . 5 . Age 12 year old . 6 . No prior allogeneic transplant 7 . Karnofsky performance score Lansky PlayPerformance least 80 . 8 . Signed informed consent adult minor provision pediatric assent parental permission . 1 . Age &lt; 12 year old . 2 . Patients require &gt; 2 course induction chemotherapy achieve remission status . 3 . HIV infection 4 . Tuberculosis Infection 5 . Chronic Obstructive Pulmonary Disease 6 . Pregnancy ( positive serum bHCG ) breastfeed 7 . Creatinine clearance nuclear medicine GFR &lt; 50 mL/min 8 . Cardiac ejection fraction &lt; 50 % 9. bilirubin &gt; 2 × upper limit normal ALT &gt; 4 × upper limit normal unresolved venoocclusive disease . 10 . Pulmonary disease FVC , FEV1 DLCO parameter &lt; 45 % predict ( correct hemoglobin ) O2 saturation &lt; 92 % room air . 11 . Karnofsky performance score Lansky PlayPerformance Scale &lt; 80 12 . Uncontrolled viral , bacterial , fungal infection time study enrollment 13 . Availability willing fully MHCmatched relate donor . 14 . Positive cytotoxic recipientdonor crossmatch positive HLA antibody screen donordisparate antigen . 15 . Any active infection . 16 . Unable obtain informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>cancer</keyword>
	<keyword>leukemia</keyword>
	<keyword>transplant</keyword>
	<keyword>bone marrow</keyword>
</DOC>